Danielle Bello, MD
Surgeon
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Request an Appointment
About Me
- Assistant Attending Surgeon
I am a surgical oncologist specializing in the care of patients with cutaneous malignancies (cancer that begins in cells that form the outer layer of the skin). These include melanoma, Merkel cell carcinoma, squamous cell carcinoma, basal cell carcinoma, and sweat gland tumors.
I see between 800 and 1,000 patients with cutaneous malignancies each year at MSK locations.
Read more
When patients come to me, they are often concerned about what their diagnosis means for their well-being and quality of life. I understand that a cancer diagnosis can be unnerving, and I take the time to answer patients’ questions about their disease patiently and empathetically. At Memorial Sloan Kettering Cancer Center, I work closely with colleagues across medical oncology, radiation oncology, pathology, nursing, and supportive care, who all specialize in the treatment of cutaneous malignancies. We spend time with our patients and their loved ones to understand their unique needs and wishes and ultimately, to recommend a treatment plan that is best for them.
I decided to pursue a career in oncology because I felt that this field was where I could make a difference. Most people will be affected by cancer at some point in their lives, either personally or through connection to a loved one, and this can take both a physical and an emotional toll. I wanted to be a part of their solution—not just by surgically treating their disease, but also by supporting them in their journey and individualizing their care so they get the best possible treatment for them. It is important to me that patients and their caregivers know that they are receiving personalized, state-of-the-art care and feel uplifted by our team of experts at each step in the process.
In addition to providing compassionate care to all who come to me, I am committed to bettering outcomes for patients with cutaneous malignancies through the study of different subsets of melanoma, such as acral melanoma. The less common types of melanomas are genetically distinct from the more common cutaneous melanomas. By better understanding these differences, I believe that we can improve how we care for people with these diseases.
Beyond researching these subsets, I am also investigating new ways to combine surgery with immunotherapy to boost outcomes in patients with advanced or melanoma that has metastasized or spread to other parts of the body. I am currently involved in studies aimed at defining the role of injecting highly concentrated drugs directly into skin lesions for patients with metastatic disease to improve their outcomes.
I enjoy spending time with my husband and three children and traveling together when we can.
A surgeon is a doctor with special training in many kinds of surgery.
My Specialties
- Melanoma
- Merkel Cell Carcinoma
- Squamous Cell Carcinoma
- Basal Cell Carcinomas
- Sweat Gland Tumors
Education
- MD, Mount Sinai School of Medicine
Residencies
- Surgery – Yale University School of Medicine
Awards and Honors
- David and Monica Gorin Award of Courage Fellow, Memorial Sloan Kettering Cancer Center (2017-2018)
Fellowships
- Surgical Oncology – Memorial Sloan Kettering Cancer Center
Board Certifications
- General Surgery, Surgical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Bello sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Bello
- A Phase 2 Study of L19IL2 and L19TNF With Pembrolizumab in People With Melanoma
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Kurtansky NR, Manci RN, Bello DM, Adamson AS, Shoushtari AN, Wehner MR, Ariyan CE, Marghoob AA, Marchetti MA, Rotemberg V. Risk of nonacral cutaneous melanoma after the diagnosis of acral melanoma. Br J Dermatol. 2022 Mar 23. doi: 10.1111/bjd.21251. Online ahead of print. PMID: 35318644 No abstract available.
Thomas D, Bello DM. Adjuvant immunotherapy for melanoma. J Surg Oncol. 2021 Mar;123(3):789-797.
Sahu, A, Oh, Y, Peterson G. Cordova M, Navarrete-Dechent C, Gill M, Alessi-Fox C, Gonzalez S, Phillips W, Wilson S, Afzalneia R, Rose R, Mohsen A, Bello D, Marghoob A, Rossi A, Wolchok JD, Merghoub T, Rotemberg V, Chen CSJ, Rajadhyaksha M In vivo optical imaging-guided targeted sampling for precise diagnosis and molecular pathology. Sci Rep. 2021 Nov 30;11(1):23124.
Read more
Bello DM, Faries MB. The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes). Ann Surg Oncol. 2020 Jan;27(1):15-21.
Bello DM, Ariyan CE. ASO Author Reflections: Is There a Re-invigorated Role for Melanoma Metastasectomy in a Checkpoint Blockade Era? Ann Surg Oncol. 2020 Jan 17.
Bello DM. Indications for the surgical resection of stage IV disease. J Surg Oncol. 2019
Bello DM, Panageas KS, Hollmann TJ, Shoushtari AN, Chapman P, Postow MA, Callahan MK, Wolchok JD, Brady MS, Coit D, Ariyan CE. Outcomes of Patients with Metastatic Melanoma Selected for Surgery After Immunotherapy. Plenary presentation at the 71st Annual Meeting of the Society of Surgical Oncology, March 21-24, 2018, Chicago, IL.
Bello DM, Ariyan CE. Adjuvant Therapy in the Treatment of Melanoma. Ann Surg Oncol. 2018 Jul;25(7):1807-1813.
Bello DM, Panageas KS, Hollmann T, Shoushtari AN, Momtaz P, Chapman PB, Postow MA, Callahan MK, Wolchok JD, Brady MS, Coit DG, Ariyan CE. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. Ann Surg Oncol. 2019 Dec 17.
Bello DM, Han G, Jackson L, Bulloch K, Ariyan S, Narayan D, Rothberg BG, Han D. The Prognostic Significance of Sentinel Lymph Node Status for Patients with Thick Melanoma. Ann Surg Oncol. 2016 Dec;23(Suppl 5):938-945.
Bello DM, Chou JF, Panageas KS, Brady MS, Coit DG, Carvajal RD, Ariyan CE. Prognosis of acral melanoma: a series of 281 patients. Ann Surg Oncol. 2013 Oct;20(11):3618-25.
Visit PubMed for a full listing of Dr. Bello’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Danielle Bello discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].